✦ LIBER ✦

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study

✍ Scribed by Pivot, Xavier; Gligorov, Joseph; Müller, Volkmar; Barrett-Lee, Peter; Verma, Sunil; Knoop, Ann; Curigliano, Giuseppe; Semiglazov, Vladimir; López-Vivanco, Guillermo; Jenkins, Valerie; Scotto, Nana; Osborne, Stuart; Fallowfield, Lesley

Book ID: 123034446
Publisher: The Lancet
Year: 2013
Tongue: English
Weight: 213 KB
Volume: 14
Category: Article
ISSN: 1470-2045
DOI: 10.1016/S1470-2045(13)70383-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

445 PrefHer: a Clinical Trial to Evaluat

445 PrefHer: a Clinical Trial to Evaluate Patient Preference for Trastuzumab Administered Subcutaneously or Intravenously in Patients with HER2-positive Early Breast Cancer

✍ X. Pivot; A. Knoop; G. Curigliano; P. Barrett-Lee; M. Lichinitser; V. Mueller; C 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 60 KB

1BA Subcutaneous Administration of Trast

1BA Subcutaneous Administration of Trastuzumab in Patients with HER2-positive Early Breast Cancer: Results From the Phase III Randomised, Open-label, Multi-centre Neoadjuvant-adjuvant HannaH Study

✍ C. Jackisch; D. Stroyakovskiy; S. Muehlbauer; D. Heinzmann; M.V. Kopp; J.S. Ahn; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Subcutaneous versus intravenous administ

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial

✍ Gustavo Ismael; Roberto Hegg; Susanne Muehlbauer; Dominik Heinzmann; Bert Lum; S 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 245 KB

Comparison of Subcutaneous and Intraveno

Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2-Positive Breast Cancer

✍ Wynne, Chris; Harvey, Vernon; Schwabe, Christian; Waaka, Devonie; McIntyre, Chri 📂 Article 📅 2013 🏛 Sage Publications 🌐 English ⚖ 268 KB

Efficacy and safety of neoadjuvant pertu

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

✍ Luca Gianni; Tadeusz Pienkowski; Young-Hyuck Im; Laslo Roman; Ling-Ming Tseng; M 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 217 KB

Lapatinib with trastuzumab for HER2-posi

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

✍ De Azambuja, Evandro (author);Holmes, Andrew P. (author);Piccart-Gebhart, Martin 📂 Article 📅 2014 🏛 Lancet Publishing Group 🌐 English ⚖ 325 KB